Johnson & Johnson Partners with Sail Biomedicines to Advance In Vivo CAR-T Therapies for Immune-Mediated Diseases
Johnson & Johnson has announced a broad strategic collaboration with Sail Biomedicines, a biotechnology company pioneering the development of in vivo chimeric antigen receptor T-cell (CAR-T) therapies for immune-mediated diseases. The partnership marks a significant step in Johnson & Johnson’s continued investment in next-generation cell therapy technologies aimed at transforming the treatment landscape for chronic autoimmune and inflammatory disorders.
As part of the agreement, Johnson & Johnson will collaborate with Sail to advance the company’s lead in vivo CAR-T program while also supporting the development of its broader technology platform. The collaboration includes opportunities to expand the application of Sail’s innovative platform to additional disease targets over time. In addition to the research partnership, Johnson & Johnson will make a substantial equity investment in Sail and has secured an exclusive option to acquire the company for $2.58 billion, underscoring its long-term commitment to this emerging therapeutic field.
Expanding the Promise of In Vivo CAR-T Therapy
CAR-T therapy has already transformed the treatment of several blood cancers by genetically modifying a patient’s T cells to recognize and eliminate cancer cells. However, traditional CAR-T therapies require immune cells to be collected from the patient, engineered in specialized manufacturing facilities, and then reinfused following a complex production process.
Sail Biomedicines is developing a different approach known as in vivo CAR-T therapy. Rather than removing immune cells from the patient’s body for laboratory modification, Sail’s technology is designed to genetically reprogram T cells directly inside the patient. This streamlined strategy has the potential to simplify treatment, reduce manufacturing complexity, improve accessibility, and shorten the time between diagnosis and therapy.
Beyond cancer, researchers believe in vivo CAR-T technology could provide durable immune system reprogramming for patients with autoimmune and immune-mediated diseases, potentially offering long-lasting disease control or even curative treatment approaches.
Collaboration Focuses on Immune-Mediated Diseases
The initial focus of the collaboration will be Sail’s lead program targeting immune-mediated diseases. These conditions occur when the body’s immune system mistakenly attacks healthy tissues, leading to chronic inflammation and progressive organ damage.
Although many existing therapies can reduce inflammation or suppress immune activity, they often require lifelong treatment and may not provide lasting remission.
By contrast, in vivo CAR-T therapies seek to reset or reprogram the immune system itself, addressing the underlying biological mechanisms responsible for disease development rather than simply managing symptoms.
Johnson & Johnson and Sail intend to combine their complementary scientific expertise to accelerate development of these innovative therapies with the goal of improving long-term outcomes for patients living with complex immune disorders.
A New Frontier in Cell Therapy
Industry experts increasingly view in vivo CAR-T therapy as one of the most promising advances in biotechnology.
Traditional CAR-T therapies have demonstrated remarkable success in hematologic cancers, but their manufacturing process remains expensive, individualized, and logistically challenging.
The in vivo approach aims to overcome many of these limitations by delivering genetic programming directly into patients, enabling immune cells to become therapeutic agents without requiring ex vivo manipulation.
If successful, this technology could make CAR-T therapies more scalable, broadly accessible, and potentially applicable across a much wider range of diseases.
Researchers also believe that directly reprogramming immune cells inside the body could support durable immune reset, reducing the need for continuous immunosuppressive medications.
Johnson & Johnson Strengthens Its Leadership in Immunology
Johnson & Johnson has established a strong position in immunology through the development of therapies for inflammatory bowel disease, psoriasis, rheumatoid arthritis, and several other autoimmune disorders.
The company has also become a major player in cell therapy through investments in oncology-focused CAR-T treatments.
The new partnership with Sail reflects Johnson & Johnson’s strategy of bringing together these two areas of expertise—immunology and cellular engineering—to develop next-generation therapies capable of fundamentally changing disease management.
John Reed, Executive Vice President of Innovative Medicine Research & Development at Johnson & Johnson, emphasized the importance of pursuing therapies capable of delivering deeper and more durable disease control for patients with serious immune-mediated conditions.
He noted that despite significant progress in recent years, many patients continue to experience disease progression or require long-term treatment with medications that primarily control symptoms rather than modify the disease itself.
According to Reed, Sail’s platform offers an innovative approach for harnessing the therapeutic power of CAR-T technology in a simpler and potentially more scalable manner, with the potential to redefine treatment for immune-mediated diseases.
Building on Existing CAR-T Expertise
Johnson & Johnson has steadily expanded its capabilities in cellular therapies, particularly in oncology, where CAR-T treatments have demonstrated meaningful clinical benefits for patients with difficult-to-treat blood cancers.
The collaboration with Sail broadens the company’s reach into the emerging field of in vivo CAR-T technologies.
Rather than replacing its existing programs, the partnership complements Johnson & Johnson’s broader strategy of investing in multiple innovative therapeutic platforms capable of addressing diseases through immune system engineering.
The agreement also positions the company at the forefront of immune reset technologies, an area receiving growing attention across the biotechnology industry.
Scientists increasingly recognize that resetting dysfunctional immune responses could potentially provide lasting remission—or even cures—for certain autoimmune disorders that currently require lifelong management.
Platform Expansion Beyond the Lead Program
While the initial collaboration centers on Sail’s lead immune-mediated disease candidate, the agreement also provides opportunities to explore the company’s underlying technology platform across multiple additional therapeutic targets.
As research progresses, Johnson & Johnson and Sail may evaluate the platform’s potential application in other immune disorders and potentially additional disease areas where immune cell reprogramming may offer therapeutic benefit.
This flexible structure allows the collaboration to evolve alongside scientific discoveries while maximizing the value of Sail’s proprietary platform technology.
Financial Terms of the Agreement
Under the terms of the collaboration, Johnson & Johnson will provide total initial payments valued at $785 million.
These include:
- A $465 million equity investment in Sail Biomedicines.
- Additional funding supporting research collaboration and platform development.
The agreement also includes up to $140 million in milestone-based payments tied to the achievement of specified development objectives.
In addition, Johnson & Johnson has secured an exclusive option to acquire Sail Biomedicines for an additional payment of $2.58 billion should it decide to exercise that option in the future.
The option structure allows Johnson & Johnson to participate in Sail’s ongoing scientific progress while preserving flexibility regarding a full acquisition.
Expected Financial Impact
Johnson & Johnson indicated that, assuming the acquisition option is exercised, the transaction is expected to reduce adjusted operational earnings per share and adjusted earnings per share by approximately $0.18 during 2026.
The projected impact would increase to approximately $1.28 per share during 2027, reflecting continued investment associated with the transaction.
The company also noted that updated financial guidance has been included in its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.
Regulatory Review Still Required
Completion of the various components of the agreement remains subject to customary regulatory approvals and other closing conditions.
The collaboration activities may begin according to the agreed development timelines, while any future acquisition would require Johnson & Johnson to formally exercise its exclusive purchase option and satisfy applicable regulatory requirements.
Advancing the Future of Precision Immunotherapy
The collaboration between Johnson & Johnson and Sail Biomedicines reflects the growing momentum behind next-generation immune engineering technologies. By combining Johnson & Johnson’s extensive experience in immunology, drug development, and commercialization with Sail’s innovative in vivo CAR-T platform, the partnership aims to accelerate the development of therapies capable of fundamentally changing how immune-mediated diseases are treated.
If successful, in vivo CAR-T therapies could overcome many of the logistical limitations associated with conventional cell therapies while expanding access to highly personalized immune-based treatments. The partnership also reinforces Johnson & Johnson’s broader strategy of investing in transformative technologies that address the root causes of disease rather than simply managing symptoms. As research advances, the collaboration has the potential to open new therapeutic opportunities across multiple disease areas and contribute to the next generation of precision medicine.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.